Angiogenesis in prostate cancer: Onset, progression and imaging

BJU International

Volumn 110, Issue 11 C, 2012, Pages

  Russo, Giovanna ^a,b   Mischi, Massimo ^a   Scheepens, Wout ^c   De La Rosette, Jean J ^b   Wijkstra, Hessel ^a,b  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c CATHARINA HOSPITAL   (Netherlands)

Author keywords

Angiogenesis; Biomedical imaging; MRI; Prostate cancer; US

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANGIOPOIETIN; ANGIOSTATIN; ANTIANDROGEN; CYCLOOXYGENASE 2; CYTOKINE; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; FLUORODEOXYGLUCOSE F 18; GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERFERON; INTERLEUKIN 8; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE; MEMBRANE PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN KINASE B; SCLEROPROTEIN; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ACIDITY; ANTIANDROGEN THERAPY; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BASEMENT MEMBRANE; BINDING AFFINITY; BLOOD FLOW; BLOOD VESSEL PERMEABILITY; CANCER GRADING; CANCER GROWTH; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL MIGRATION; CELL PROLIFERATION; COLOR ULTRASOUND FLOWMETRY; DIFFUSION WEIGHTED IMAGING; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ECHOGRAPHY; ENDOTHELIUM CELL; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GROWTH STIMULATION; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; METASTASIS; MICROCIRCULATION; MICROVASCULATURE; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSRECTAL ULTRASONOGRAPHY; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; DIAGNOSTIC IMAGING; DISEASE COURSE; MALE; METHODOLOGY; PROSTATE TUMOR; VASCULARIZATION;

DIAGNOSTIC IMAGING; DISEASE PROGRESSION; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS;

MLCS; MLOWN;

EID: 84873249168     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11444.x     Document Type: Review

References (130)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6
3. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6 (Pubitemid 20020880)
4. Weidner N, Folkman J, Pozza F et al. Tumor angiogenesis: a new signifi cant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst 1992; 84: 1875-87 (Pubitemid 23004615)
5. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57
6. Holmgren L, O ' Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. N at Med 1995; 1: 149-53
7. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. C ell 1996; 8 6: 353-64 (Pubitemid 26272076)
8. Alitalo K, Tamela T, Petrova TV. Lymphangiogenesis in development and human disease. N ature 2005; 4 38: 946-53 (Pubitemid 43093960)
9. Dickinson L, Ahmed HU, Allen C et al. Magnetic resonance imaging for the detection, localization, and characterisation of prostate cancer: recommendations from a European consensus meeting. E ur Urol 2011; 5 4: 477-94
10. Smeenge M, Barentsz J, Cosgrove D et al. Role of transrectal ultrasound in focal therapy of prostate cancer: report from a consensus panel. BJU Int 2012; [ Epub ahead of print ]. DOI: 10.1111/j.1464-410X.2012.11072.x
11. Sabatini DM. mTOR and cancer: insights into a complex relationship. Cancer 2006; 6: 729-34 (Pubitemid 44286004)
12. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fi broblasts by p53 regulation of thrombospondin-1. S cience 1994; 2 65: 1582-4 (Pubitemid 24308973)
13. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-6 (Pubitemid 36749215)
14. Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature 2005; 438: 937-94
15. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22 (Pubitemid 29038270)
16. Friesel RE, Maciag T. Molecular mechanisms of angiogenesis: fi broblast growth factor signal transduction. FASEB J 1995; 9: 919-25
17. Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J Cell Biol 1994; 1 25: 917-28 (Pubitemid 24151185)
18. Wang B, Hendricks DT, Wamunyokoli F, Parker MI. A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res 2006; 66: 3071-7
19. Sankar S, Mahooti-Brooks N, Bensen L, McCarthy TL, Centrella M, Madri JA. Modulation of transforming growth factor beta receptor levels on microvascular endothelial cells during in vitro angiogenesis. J Clin Invest 1996; 97: 1436-46 (Pubitemid 26097033)
20. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. N at Rev Cancer 2002; 2: 161-74 (Pubitemid 37328786)
21. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposis sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-23 (Pubitemid 40411498)
22. O ' Reilly MS, Holmgren L, Shing Y et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. C ell 1994; 79: 315-28 (Pubitemid 24324921)
23. Chen H, Herndon ME, Lawler J. The cell biology of thrombospondin-1. Matrix Biol 2000; 19: 597-614
24. O ' Reilly MS, Boehm T, Shing Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85 (Pubitemid 28015876)
25. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411: 375-9
26. Yu JL, Rak JW. Host microenvironment in breast cancer development: infl ammatory and immune cells in tumour angiogenesis and arteriogenesis. Breast Cancer Res 2003; 5: 83-8
27. Zhong H, De Marzo AM, Laughner E et al. Overexpression of hypoxiainducible factor 1 alpha in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5
28. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008; 8: 851-64
29. Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 2010; 17: 206-25
30. Lyden D, Hattori K, Dias S et al. Impaired recruitment of bone-marrowderived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194-201 (Pubitemid 33063774)
31. Dome B, Hendrix MJ, Paku S, Tovari J, Timar J. Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am J Pathol 2007; 170: 1-15 (Pubitemid 47339184)
32. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003; 3: 411-21 (Pubitemid 37328845)
33. Weidner N, Carroll R, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-9 (Pubitemid 24058195)
34. Sedelaar JP, van Leenders GJ, Hulsbergen CA et al. Microvessel density: correlation between contrast ultrasonography and histology of prostate cancer. Eur Urol 2001; 40: 285-93 (Pubitemid 34701898)
35. Schoell WM, Pieber D, Reich O et al. Tumor angiogenesis as a prognostic factor in ovarian carcinoma: quantifi cation of endothelial immunoreactivity by image analysis. Cancer 1997; 80: 2257-62 (Pubitemid 28007396)
36. Pezzella F, Pastorino U, Tagliabue E et al. Non small cell lung carcinoma tumour growth without morphological evidence of neo-angiogenesis. Am J Pathol 1997; 151: 1417-23 (Pubitemid 27479772)
37. Korkolopoulou P, Konstantinidou AE, Kavantzas N et al. Morphometric microvascular characteristics predict prognosis in superfi cial and invasive bladder cancer. Virchows Arch 2001; 438: 603-11 (Pubitemid 32662380)
38. Jain RK. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J Control Release 2001; 74: 7-25 (Pubitemid 32727605)
39. Hashizume H, Baluk P, Morikawa S et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000; 156: 1363-80 (Pubitemid 30660013)
40. Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF. Vascular permeability, vascular hyperpermeability and angiogenesis. A ngiogenesis 2008; 1 1: 109-19
41. Choi YJ, Kim JK, Kim N et al. Functional MR imaging of prostate cancer. Radiographics 2007; 27: 63-75
42. Li Y, Cozzi PJ. Angiogenesis as a strategic target for prostate cancer therapy. Med Res Rev 2009; 30: 23-66
43. Chung LW, Baseman A, Assikis V, Zhau HE. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 2005; 1 73: 10-20 (Pubitemid 39627663)
44. Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004; 17: 292-306 (Pubitemid 41646608)
45. Ferrer FA, Miller LJ, Andrawis RI et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998; 51: 161-7 (Pubitemid 28092530)
46. Ravi R, Mookerjee B, Bhujwalla ZM et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia inducible factor 1alpha. Genes Dev 2000; 14: 34-44 (Pubitemid 30051577)
47. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002; 1: 219-27 (Pubitemid 41039145)
48. Botelho F, Pina F, Lunet N. VEGF and prostate cancer: a systematic review. Eur J Cancer Prev 2010; 19: 385-92
49. Shariat SF, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM, Slawin KM. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 2004; 22: 1655-63 (Pubitemid 41079804)
50. Kwabi-Addo B, Ozen M, Ittmann M. The role of fi broblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004; 11: 709-24 (Pubitemid 40065546)
51. Bok RA, Halabi S, Fei DT et al. Vascular endothelial growth factor and basic fi broblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 2001; 61: 2533-6 (Pubitemid 32685834)
52. Russell J, Bennett S, Stricker P. Growth factor involvement in progression of prostate cancer. Clin Chem 1998; 44: 705-23 (Pubitemid 28176012)
53. Wikstr ö m P, Damber J, Bergh A. Role of transforming growth factor-beta1 in prostate cancer. Microsc Res Tech 2001; 52: 411-9 (Pubitemid 32167829)
54. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. C ancer Metastasis Rev 2006; 25: 9-34 (Pubitemid 43723979)
55. Brehmer B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP-2 and-9) and their inhibitors (TIMP-1 and-2) in prostate cancer tissue. P rostate Cancer Prostatic Dis 2003; 6: 217-22 (Pubitemid 37185149)
56. Escaff S, Fernandez JM, Gonzalez LO et al. Study of matrix metalloproteinases and their inhibitors in prostate cancer. Br J Cancer 2010; 102: 922-9
57. Zhu ML, Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 2008; 15: 841-9
58. Gordon IO, Tretiakova MS, Noffsinger AE, Hart J, Reuter VE, Al-Ahmadie HA. Prostate-specifi c membrane antigen expression in regeneration and repair. Mod Pathol 2008; 12: 1421-7
59. Ghosh A, Heston WD. Tumor target prostate specifi c membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91: 528-39
60. Lilja H, Ulmert D, Vickers AJ. Prostate-specifi c antigen and prostate cancer: prediction, detection and monitoring. N at Rev Cancer 2008; 8: 268-78 (Pubitemid 351430866)
61. Firlej V, Mathieu JR, Gilbert C et al. Thrombospondin-1 triggers cell migration and development of advanced prostate tumors. Cancer Res 2011; 71: 7649-58
62. Inoue K, Slaton JW, Kim SJ et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 2000; 60: 2290-9 (Pubitemid 30225196)
63. Persano L, Moserle L, Esposito G et al. Interferon-alpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. Carcinogenesis 2009; 30: 851-60
64. Zhong H, Semenza GL, Simons JW, De Marzo AM. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev 2004; 28: 88-93 (Pubitemid 38448745)
65. Cvetkovic D, Movsas B, Dicker AP. Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. Urology 2001; 57: 821-5
66. Izawa JI, Dinney CPN. The role of angiogenesis in prostate and other urologic cancers: a review. CMAJ 2001; 164: 662-70 (Pubitemid 32193868)
67. Horii K, Suzuki Y, Kondo Y et al. Androgen-dependent gene expression of prostate-specifi c antigen is enhanced synergistically by hypoxia in human prostate cancer cells. Mol Cancer Res 2007; 5: 383-91 (Pubitemid 46707000)
68. Brawer MK, Deering RE, Brown M et al. Predictors of pathologic stage in prostatic carcinoma: the role of neovascularity. Cancer 1994; 73: 678-87 (Pubitemid 24046612)
69. Di Lorenzo G, De Placido S, Autorino R et al. Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease. Prostate Cancer Prostatic Dis 2005; 8: 54-9
70. Silberman MA, Partin AW, Veltri RW et al. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 1997; 79: 772-9 (Pubitemid 27076343)
71. Lissbrant IF, Stuttin P, Damber JE et al. Vascular density is a predictor of cancer-specifi c survival in prostatic carcinoma. Prostate 1997; 33: 38-45 (Pubitemid 27381593)
72. Rubin MA, Buyyounouski M, Bagiella E et al. Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. U rology 1999; 5 3: 542-7 (Pubitemid 29136199)
73. Erbersdobler A, Isbarn H, Dix K et al. Prognostic value of microvessel density in prostate cancer: a tissue microarray study. World J Urol 2010; 28: 687-92
74. Schlemmer HP, Merkle J, Grobholz R et al. Can pre-operative contrastenhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol 2004; 14: 309-17 (Pubitemid 38181089)
75. Mazzucchelli R, Montironi R, Santinelli A et al. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. P rostate 2000; 45: 72-9
76. Krouskop TA, Wheeler TM, Kallel F, Garra BS, Hall T. Elastic moduli of breast and prostate tissue under compression. U ltrason Imaging 1998; 20: 260-74 (Pubitemid 29168827)
77. Bubendorf L, Schopfer A, Wagner U et al. Metastatic patterns of prostate cancer: an autopsy study of 1, 589 patients. Hum Pathol 2000; 31: 578-82
78. Halpern EJ. Contrast-enhanced ultrasound imaging of prostate cancer. Rev Urol 2006; 8: S29-37
79. Alonzi R, Padhani AR. Dynamic contrast enhanced MRI in prostate cancer. Eur J Radiol 2007; 63: 335-50 (Pubitemid 47321040)
80. Padhani AR, Harvey CJ, Cosgrove DO. Angiogenesis imaging in the management of prostate cancer. Nat Clin Pract Urol 2005; 2: 596-607 (Pubitemid 43135243)
81. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. R adiology 2007; 2 43: 28-53 (Pubitemid 46579693)
82. Scheidler J, Hricak H, Vigneron DB et al. Prostate cancer: localization with three dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 1999; 213: 473-80 (Pubitemid 29510595)
83. Vlaardingenbroek MT, den Boer JA. Magnetic Resonance Imaging Theory and Practice, 3rd edn. Berlin: Springer, 2003
84. Kim CK, Park BK, Kim B. High-b-Value diffusion-weighted imaging at 3T to detect prostate cancer: comparisons between b values of 1, 000 and 2, 000 s/mm 2. AJR Am J Roentgenol 2010; 194: W33-7
85. Tan CH, Wang J, Kundra V. Diffusion weighted imaging in prostate cancer. Eur Radiol 2011; 21: 593-603
86. Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol 2011; [ Epub ahead of print ]. DOI: 10.1016/j.urolonc.2010.08. 008
87. Farsad M, Schiavina R, Castellucci P et al. Detection and localization of intraprostate cancer: correlation of 11C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005; 46: 1642-9 (Pubitemid 46211588)
88. Liu IJ, Zafar MB, Lai YH et al. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ confi ned prostate cancer. Urology 2001; 57: 108-11 (Pubitemid 32065829)
89. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F-or 11C-acetate, and 18F-or 11C-choline. J Nucl Med 2011; 52: 81-9
90. Taneja SS. ProstaScint scan: contemporary use in clinical practice. Rev Urol 2004; 6: S19-28
91. Mouraviev V, Madden JF, Broadwater G et al. Use of 111In-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland. J Urol 2009; 182: 938-47
92. Sedelaar JP, van Roermund JG, van Leenders GL, Hulsbergenvan de Kaa CA, Wijkstra H, de la Rosette JJ. Three dimensional grayscale ultrasound: evaluation of prostate cancer compared with benign prostatic hyperplasia. U rology 2001; 5 7: 914-20 (Pubitemid 32405313)
93. Kuligowska E, Barish MA, Fenlon HM, Blake M. Predictors of prostate carcinoma: accuracy of gray-scale and color Doppler US and serum markers. Radiology 2001; 220: 757-64 (Pubitemid 32799987)
94. Halpern EJ, Frauscher F, Strup SE, Nazarian LN, O ' Kane P, Gomella LG. Prostate: high frequency Doppler US imaging for cancer detection. Radiology 2002; 225: 71-7
95. Eisenberg ML, Cowan JE, Carroll PR, Shinohara K. The adjunctive use of power Doppler imaging in the preoperative assessment of prostate cancer. BJU Int 2009; 105: 1237-41
96. Wink M, Frauscher F, Cosgrove D et al. Contrast-enhanced ultrasound and prostate cancer: a multicentre European research coordination project. Eur Urol 2008; 54: 982-92
97. Smeenge M, Mischi M, Laguna Pes MP, De la Rosette JJ, Wijkstra H. Novel contrast-enhanced ultrasound imaging in prostate cancer. World J Urol 2011; 29: 581-7
98. Kuenen MPJ, Mischi M, Wijkstra H. Contrast-ultrasound diffusion imaging for localization of prostate cancer. IEEE Trans Med Imaging 2011; 30: 1493-502
99. Lavoipierre AM, Snow RM, Frydenberg M et al. Prostatic cancer: role of color Doppler imaging in transrectal sonography. AJR Am J Roentgenol 1998; 171: 205-10 (Pubitemid 28308676)
100. Urban M, Smerhovsky ' Z, Zachoval R, Lukes M, Heracek J. Value of power Doppler sonography with 3D reconstruction in preoperative diagnostics of extraprostatic tumor extension in clinically localized prostate cancer. Int J Urol 2008; 15: 68-75
101. Mitterberger MJ, Aigner F, Horninger W et al. Comparative effi ciency of contrast-enhanced colour Doppler ultrasound targeted versus systematic biopsy for prostate cancer detection. Eur Radiol 2010; 20: 2791-6
102. Linden RA, Trabulsi EJ, Forsberg F, Gittens PR, Gomella LG, Halpern EJ. Contrast enhanced ultrasound fl ash replenishment method for directed prostate biopsies. J Urol 2007; 178: 2354-8 (Pubitemid 350052168)
103. Seitz M, Gratzke C, Schlenker B et al. Contrast-enhanced transrectal ultrasound (CE-TRUS) with cadence contrast pulse sequence (CPS) technology for the identifi cation of prostate cancer. Urol Oncol 2011; 29: 295-301
104. Kirkham APS, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate?. Eur Urol 2006; 50: 1163-75 (Pubitemid 44692933)
105. Graser A, Heuck A, Sommer B et al. Per-sextant localization and staging of prostate cancer: correlation of imaging fi ndings with whole-mount step section histopathology. AJR Am J Roentgenol 2007; 188: 84-90 (Pubitemid 46012493)
106. Ogura K, Maekawa S, Okubo K et al. Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: correlation with histopathologic results. Urology 2001; 57: 721-6
107. Futterer JJ, Heijmink SW, Sceenen TW et al. Prostate cancer localization with dynamic contrast enhanced MR imaging and proton MR spectroscopic imaging. Radiololgy 2006; 12: 449-58 (Pubitemid 44632891)
108. Futterer JJ, Scheenen TW, Heijmink SW et al. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol 2007; 42: 116-22 (Pubitemid 46104892)
109. Tofts PS, Brix G, Buckley DL et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10: 223-32 (Pubitemid 29463104)
110. Bloch BN, Furman-Haran E. Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrastenhanced and T2-weighted MR imaging-initial results. Radiology 2007; 245: 176-85 (Pubitemid 47417801)
111. Casciani E, Gualdi G. Prostate cancer: value of magnetic resonance spectroscopy 3D chemical shift imaging. Abdom Imaging 2006; 31: 490-9 (Pubitemid 46352054)
112. Kurhanewicz J, Vigneron D, Carroll P, Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol 2008; 18: 71-7 (Pubitemid 350307535)
113. Anger HO. Scintillation camera. Rev Sci Instrum 1958; 29: 27-33
114. Levin CS. Primer on molecular imaging technology. Eur J Nucl Med Mol Imaging 2005; 32: 325-45
115. Conti M. Focus on time-of-fl ight PET the benefi ts of improved time resolution. Eur J Nucl Med Mol Imaging 2011; 38: 1147-57
116. Nu ñ ez R, Macapinlac HA, Yeung HW et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 2002; 43: 46-55 (Pubitemid 34101187)
117. Szabo T. Diagnostic Ultrasound Imaging: inside out. London: Elsevier Academic Press, 2004
118. Frinking PJ, Boukaz A, Kirkhorn J, Ten Cate FJ, de Jong N. Ultrasound contrast imaging: current and new potential methods. Ultrasound Med Biol 2000; 26: 965-75
119. Goossen TE, de la Rosette JJ, Hulsbergen CA, van Leenders GJ, Wijkstra H. The value of dynamic contrast enhanced power Doppler ultrasound imaging in the localization of prostate cancer. Eur Urol 2003; 43: 124-31 (Pubitemid 36221964)
120. Hoff L. Acoustic Characterization of Contrast Agents for Medical Ultrasound Imaging. Dordrecht: Kluwer Academic Publisher, 2001
121. de Jong N, Emmer M, van Wamel A, Versluis M. Ultrasonic characterization of ultrasound contrast agents. Med Biol Eng Comput 2009; 47: 861-73
122. Shi WT, Forsberg F. Ultrasonic characterization of the nonlinear properties of contrast microbubbles. Ultrasound Med Biol 2000; 26: 93-104 (Pubitemid 30045527)
123. Quaia E. Microbubble ultrasound contrast agents: an update. Eur Radiol 2007; 17: 1995-2008 (Pubitemid 47097457)
124. Wei K, Jayaweera AR, Firoozan S et al. Quantifi cation of myocardial blood fl ow with ultrasound-induced destruction of microbubbles administrated as a contrast venous infusion. C irculation 1998; 9 7: 473-83
125. Halpern EJ, Ramey JR, Strup SE, Frauscher F, McCue P, Gomella LG. Detection of prostate carcinoma with contrast enhanced sonography using intermittent harmonic imaging. Cancer 2005; 104: 2373-83 (Pubitemid 41691558)
126. Elie N, Kaliski A, Pronneau P, Opolon P, Roche A, Lassau N. Methodology for quantifying interactions between perfusion evaluated by DCE-US and hypoxia throughout tumor growth. Ultrasound Med Biol 2007; 33: 549-60 (Pubitemid 46476828)
127. Cosgrove D, Lassau N. Imaging of perfusion using ultrasound. Eur J Nucl Med Mol Imaging 2010; 37: S65-85
128. Mischi M, Kuenen MPJ, Wijkstra H. Angiogenesis imaging by spatiotemporal analysis of ultrasound contrast agent dispersion kinetics. IEEE Trans UFFC 2012; 59: 621-9
129. Tardy I, Pochon S, Theraulaz M et al. Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55. Invest Radiol 2010; 45: 573-8
130. Wijkstra H. BR55 in prostate cancer: an exploratory clinical trial. Clin Trials 2012; NCT01253213